A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (J2A-MC-GZGT)

Eli Lilly Japan K.K.0 个研究点目标入组 520 人开始时间: 待定最近更新: 2024年3月28日

适应症

试验速览

暂无简介。

•Have Type 2 Diabetes
•Have HbA1c >=7.0% (53 mmol/mol) to <=9.5% (80 mmol/mol) despite diet and exercise treatment, as determined by the central laboratory at screening.
•Are naive to insulin therapy except for gestational diabetes or <=14 days use for acute treatment and have not used any oral or injectable antihyperglycemic medications during the 90 days preceding screening or between screening and randomization.
•Are of stable weight (+-5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight other than the lifestyle and/or dietary measures for diabetes treatment.
•Have a body mass index (BMI) >=23.0 kilogram/square meter (kg/m2) at screening.

•Have Type 1 Diabetes
•Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening, or between screening and randomization.
•Currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
•Have New York Heart Association functional classification IV congestive heart failure.
•Have acute or chronic hepatitis

Change from Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Week 40 ]

未报告次要终点

发起方